Evaluation of MCM5 in Postmenopausal Bleeding Patients

UnknownOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2023

Conditions
Endometrial Cancer
Interventions
DIAGNOSTIC_TEST

MCM5 ELISA

ADXGYNAE is a non-invasive ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the detection of endometrial cancer in women with postmenopausal bleeding who are suspected of having endometrial cancer. Participants will be asked to provide a urine specimen, which will be centrifuged before the sediment is lysed. The lysed sample will then be tested with the MCM5 ELISA.

Trial Locations (1)

M13 9WL

RECRUITING

Saint Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester

Sponsors
All Listed Sponsors
lead

Arquer Diagnostics Ltd

INDUSTRY

NCT05287048 - Evaluation of MCM5 in Postmenopausal Bleeding Patients | Biotech Hunter | Biotech Hunter